Invesco Pharmaceuticals ETF vs State Street Biotech ETF: Which Fund Is the Better Buy in 2026?

The article contrasts biotech ETF risk/return: State Street SPDR S&P Biotech ETF (XBI) delivered a stronger 1-year total return (+93.3%) but suffered a much larger 5-year max drawdown (-54.0%), versus Invesco Pharmaceuticals ETF (PJP) with a smaller drawdown (-17.5%). PJP is more income-oriented with a higher trailing dividend yield (0.90% vs 0.30%) and lower beta (0.45 vs 0.82), though it has a higher expense ratio (0.57% vs 0.35%). Overall, it frames XBI as the better long-term “buy” for capturing small-cap upside, while PJP is positioned for lower volatility and regular distributions.

Analysis

This is less a healthcare call than a factor call: XBI is effectively a levered bet on small-cap risk appetite, while PJP is a quality/carry basket with much lower dependence on external funding. In a regime where real yields stay sticky and equity breadth narrows, the cheaper-looking, higher-beta biotech basket can still be the worse risk-adjusted asset because its upside is contingent on both clinical wins and a receptive financing window.

The key second-order effect is that XBI’s rally can become self-reinforcing only if capital markets stay open for follow-on raises and IPOs; that is the point where the more speculative names inside the fund can extend runway. If that window closes, the same composition becomes a drawdown engine, while PJP’s cash-rich large-cap weightings should keep attracting defensive healthcare allocations from allocators who want earnings visibility rather than discovery optionality. LLY remains the clearest structural winner inside the space, but the concentration means PJP is more of a disguised LLY/ABBV/JNJ quality basket than a diversified healthcare trade.

Contrarian view: the market may be extrapolating a small-cap beta squeeze into a durable biotech regime shift. Over a 1-3 month horizon, the first reversal catalyst is usually rates or a broad risk-off tape; over 6-18 months, it is either failed data readouts or a shut IPO/follow-on market. If XBI keeps outperforming while funding conditions improve, the bearish relative-value case breaks; otherwise the move looks overdone versus fundamentals.

Key Decisions for Investors

• Long PJP / short XBI as a 3-6 month relative-value trade; thesis is quality/carry outperforming high-beta biotech if rates stay firm and risk appetite cools. Fade if XBI outperforms PJP by >10% or if biotech issuance reopens materially.
• Use XLV as the cleaner benchmark for defensive healthcare exposure; prefer XLV or PJP over XBI on any broad market rally that loses breadth. Best entry is on XBI strength following a biotech-specific headline spike.
• If you want single-name expression of the PJP thesis, overweight LLY and ABBV versus the ETF stack; these names capture pricing power and are less dependent on capital markets. Stop thesis if GLP-1 growth slows or margin guidance compresses.
• Set an alert on Treasury yields and high-yield spreads: a 25-50 bps drop in real yields or a noticeable tightening in spreads would be the main macro falsifier for the short-XBI view.